Previous 10 | Next 10 |
SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today a collaboration with Hospital for Special Surgery (HSS) in New York City. This well...
SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced that Ron Rocca, President and Chief Executive Officer of Exagen, will present at the Can...
Exagen Inc. (XGN) Q2 2020 Earnings Conference Call July 28, 2020 at 08.00 ET Company Participants Ron Rocca - President and Chief Executive Officer Kamal Adawi - Chief Financial Officer Mark Hazeltine - Senior Vice President of Finance & Corporate Development Conference Ca...
Image source: The Motley Fool. Exagen Inc. (NASDAQ: XGN) Q2 2020 Earnings Call Jul 28, 2020 , 8:00 a.m. ET Operator Continue reading
Exagen (NASDAQ: XGN ) : Q2 GAAP EPS of -$0.27 beats by $0.49 . More news on: Exagen Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Testing Experiencing Monthly Sequential Improvement Record Gross Margins of 63% SAN DIEGO, July 28, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today reported...
SAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced that all AVISE test offerings (CTD, Lupus, SLE Prognostic, SLE Monitor, APS, MTX and HCQ) wil...
SAN DIEGO, July 16, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced that it will release financial results for the quarter ended June 30, 2020 before t...
SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced it has entered into an exclusive worldwide license agreement with the Ohio State In...
SAN DIEGO, June 03, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today a clinical trial in collaboration with Duke University in Durham, NC. The Duke Lupu...
News, Short Squeeze, Breakout and More Instantly...
CARLSBAD, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2024. First Quarter Highlights: Recognized total revenue of $14.4 million in the ...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...
CARLSBAD, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2024, before the market opens on Monday, May 13, 2024. John Aballi, Exagen’s President and Chief Executiv...